Adverse Drug Event Monitoring Could Include Monthly Literature Reviews
Executive Summary
Pharmaceutical companies should review scientific and medical journals at least once a month as part of an adverse event reporting strategy, AstraZeneca VP-Global Drug Safety Barry Arnold said